Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

NCT03299088 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

KRAS Gene Mutation
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Trametinib

Sponsor

Jonathan Riess

Collaborators

[object Object]
[object Object]
[object Object]